Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
DRMA similar filings
- 15 Nov 23 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
- 9 Nov 23 Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- 10 Aug 23 Dermata Therapeutics Provides Corporate Update and Reports Second Quarter
- 3 Aug 23 Changes in Registrant's Certifying Accountant
- 24 May 23 Dermata Therapeutics Announces $1.8 Million Offering Priced At-The-Market Under Nasdaq Rules
- 11 May 23 Dermata Therapeutics Provides Corporate Update and Reports First Quarter
- 28 Mar 23 Other Events
Filing view
External links
EXHIBIT 16.1
August 3, 2023
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Commissioners:
We have read Item 4.01 of Dermata Therapeutics, Inc.’s Form 8-K dated August 3, 2023, and we agree with the statements set forth in Item 4.01, insofar as they relate to our firm. We have no basis to agree or disagree with other statements made by the registrant contained in Item 4.01.
Very truly yours,
/s/ Mayer Hoffman McCann P.C.
San Diego, California